Share Price and Basic Stock Data
Last Updated: November 26, 2025, 5:49 pm
| PEG Ratio | 2.87 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Poly Medicure Ltd operates in the medical equipment and accessories sector, focusing on manufacturing a range of medical devices. The company reported a market capitalization of ₹19,200 Cr and a current price of ₹1,893 per share. Over the past few years, the company has shown a consistent upward trajectory in its sales, which stood at ₹1,115 Cr for the year ending March 2023, up from ₹922 Cr in March 2022. The sales are projected to rise significantly, reaching ₹1,669 Cr by March 2025. Quarterly sales have also shown steady growth, with the most recent figures indicating sales of ₹337 Cr in September 2023, marking a continuous increase from ₹321 Cr in June 2023. The company’s operational efficiency is highlighted by an operating profit margin (OPM) of 26% for FY 2025, demonstrating strong profitability relative to its sales. This upward trend positions Poly Medicure as a robust player in the medical device industry, catering to rising healthcare demands.
Profitability and Efficiency Metrics
Poly Medicure’s profitability metrics indicate a strong financial performance, with a net profit of ₹362 Cr reported for the trailing twelve months. This reflects a significant increase from the previous year’s net profit of ₹179 Cr in March 2023. The company’s earnings per share (EPS) for March 2025 stood at ₹34.13, demonstrating robust growth in shareholder value. The return on equity (ROE) for the company was reported at 15.8%, while the return on capital employed (ROCE) was 20.1%, both of which are favorable compared to typical sector benchmarks. Additionally, the interest coverage ratio (ICR) was an impressive 45.18x, indicating that the company comfortably manages its interest obligations. However, the cash conversion cycle (CCC) of 239 days suggests that the company takes a longer time to convert its investments into cash, which could be a potential area for operational improvement.
Balance Sheet Strength and Financial Ratios
Poly Medicure’s balance sheet reflects a strong financial position, with total assets reported at ₹3,192 Cr as of March 2025, an increase from ₹1,859 Cr in March 2024. The company has maintained a conservative borrowing strategy, with total borrowings standing at ₹240 Cr, resulting in a low total debt to equity ratio of 0.06. Reserves have also seen substantial growth, reaching ₹2,868 Cr, which enhances the company’s financial stability and provides a buffer for future expansions or downturns. The current ratio of 5.18 indicates a strong liquidity position, allowing the company to meet its short-term obligations comfortably. Furthermore, the price-to-book value (P/BV) ratio is currently at 8.21x, which reflects a premium valuation compared to typical industry ranges, suggesting that investors are willing to pay more for each unit of net assets.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Poly Medicure Ltd reveals a diversified ownership structure, with promoters holding 62.42% of the total shares, indicative of strong management control and alignment with shareholder interests. Foreign institutional investors (FIIs) accounted for 9.77%, while domestic institutional investors (DIIs) held 13.53%. The public shareholding stands at 14.28%, with the total number of shareholders reaching approximately 64,400. This wide distribution among various investor categories suggests a solid level of confidence in the company’s growth prospects. Notably, the promoter holding has remained relatively stable, indicating a commitment to the company’s long-term vision. However, the declining trend in FII shareholding from 16.33% in December 2022 to 9.77% may raise concerns regarding international investor sentiment towards the company.
Outlook, Risks, and Final Insight
The outlook for Poly Medicure remains optimistic, driven by increasing demand for medical devices and a solid growth trajectory in revenue and profitability metrics. However, potential risks include the prolonged cash conversion cycle, which could impact liquidity and operational efficiency. Additionally, the dependency on domestic markets for sales could expose the company to regional economic fluctuations. The company’s substantial reserves position it well for future investments and expansion, enhancing its competitive advantage in the medical equipment sector. Ultimately, while Poly Medicure presents a compelling investment opportunity given its strong fundamentals and market position, investors should remain cautious of the operational risks and market dynamics that could affect its performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Poly Medicure Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Constronics Infra Ltd | 81.2 Cr. | 64.8 | 138/46.0 | 18.5 | 32.8 | 0.00 % | 19.7 % | 15.8 % | 10.0 |
| Centenial Surgical Suture Ltd | 41.6 Cr. | 114 | 189/82.2 | 84.1 | 0.00 % | 3.94 % | 4.64 % | 10.0 | |
| Adeshwar Meditex Ltd | 23.1 Cr. | 16.0 | 26.5/15.0 | 11.2 | 26.1 | 0.00 % | 8.27 % | 5.51 % | 10.0 |
| Poly Medicure Ltd | 19,252 Cr. | 1,900 | 3,032/1,821 | 53.2 | 288 | 0.18 % | 20.1 % | 15.8 % | 5.00 |
| Mohini Health & Hygiene Ltd | 79.8 Cr. | 43.8 | 86.9/41.2 | 23.9 | 55.7 | 0.00 % | 14.1 % | 10.0 % | 10.0 |
| Industry Average | 19,252.00 Cr | 427.72 | 26.70 | 97.34 | 0.04% | 13.22% | 10.35% | 9.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 249 | 275 | 285 | 307 | 321 | 337 | 340 | 378 | 385 | 420 | 424 | 441 | 403 |
| Expenses | 202 | 210 | 214 | 224 | 234 | 253 | 249 | 282 | 281 | 305 | 310 | 321 | 297 |
| Operating Profit | 46 | 65 | 71 | 83 | 87 | 84 | 90 | 96 | 104 | 115 | 115 | 119 | 106 |
| OPM % | 19% | 24% | 25% | 27% | 27% | 25% | 27% | 26% | 27% | 27% | 27% | 27% | 26% |
| Other Income | 5 | 9 | 15 | 9 | 14 | 15 | 17 | 15 | 17 | 27 | 24 | 27 | 43 |
| Interest | 1 | 0 | 5 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Depreciation | 14 | 14 | 14 | 15 | 16 | 16 | 16 | 16 | 20 | 21 | 22 | 21 | 23 |
| Profit before tax | 36 | 59 | 67 | 75 | 83 | 81 | 88 | 92 | 98 | 118 | 113 | 123 | 123 |
| Tax % | 26% | 27% | 25% | 22% | 24% | 23% | 26% | 26% | 25% | 26% | 25% | 25% | 24% |
| Net Profit | 27 | 44 | 50 | 59 | 63 | 62 | 65 | 68 | 74 | 87 | 85 | 92 | 93 |
| EPS in Rs | 2.81 | 4.54 | 5.21 | 6.13 | 6.54 | 6.48 | 6.78 | 7.12 | 7.71 | 8.63 | 8.41 | 9.06 | 9.19 |
Last Updated: August 20, 2025, 5:25 am
Below is a detailed analysis of the quarterly data for Poly Medicure Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 403.00 Cr.. The value appears to be declining and may need further review. It has decreased from 441.00 Cr. (Mar 2025) to 403.00 Cr., marking a decrease of 38.00 Cr..
- For Expenses, as of Jun 2025, the value is 297.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 321.00 Cr. (Mar 2025) to 297.00 Cr., marking a decrease of 24.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2025) to 106.00 Cr., marking a decrease of 13.00 Cr..
- For OPM %, as of Jun 2025, the value is 26.00%. The value appears to be declining and may need further review. It has decreased from 27.00% (Mar 2025) to 26.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from 27.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 16.00 Cr..
- For Interest, as of Jun 2025, the value is 3.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Mar 2025) to 23.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 123.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 123.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Mar 2025) to 24.00%, marking a decrease of 1.00%.
- For Net Profit, as of Jun 2025, the value is 93.00 Cr.. The value appears strong and on an upward trend. It has increased from 92.00 Cr. (Mar 2025) to 93.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.19. The value appears strong and on an upward trend. It has increased from 9.06 (Mar 2025) to 9.19, marking an increase of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:41 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 322 | 390 | 411 | 454 | 519 | 610 | 687 | 785 | 922 | 1,115 | 1,375 | 1,669 | 1,712 |
| Expenses | 246 | 304 | 323 | 361 | 397 | 479 | 520 | 569 | 707 | 847 | 1,014 | 1,214 | 1,258 |
| Operating Profit | 76 | 86 | 88 | 93 | 122 | 131 | 166 | 216 | 215 | 267 | 361 | 455 | 454 |
| OPM % | 24% | 22% | 21% | 21% | 23% | 22% | 24% | 28% | 23% | 24% | 26% | 27% | 27% |
| Other Income | 11 | 28 | 8 | 14 | 16 | 20 | 21 | 22 | 40 | 38 | 60 | 94 | 128 |
| Interest | 9 | 10 | 10 | 8 | 12 | 14 | 20 | 11 | 6 | 11 | 14 | 14 | 11 |
| Depreciation | 14 | 19 | 21 | 24 | 29 | 37 | 41 | 48 | 54 | 57 | 63 | 83 | 91 |
| Profit before tax | 63 | 85 | 65 | 75 | 97 | 100 | 126 | 180 | 195 | 237 | 344 | 453 | 481 |
| Tax % | 30% | 27% | 27% | 27% | 27% | 35% | 24% | 25% | 25% | 25% | 25% | 25% | |
| Net Profit | 45 | 62 | 48 | 55 | 71 | 65 | 96 | 136 | 147 | 179 | 258 | 339 | 362 |
| EPS in Rs | 5.11 | 7.07 | 5.47 | 6.25 | 8.00 | 7.41 | 10.86 | 14.17 | 15.28 | 18.69 | 26.91 | 33.41 | 35.72 |
| Dividend Payout % | 20% | 18% | 27% | 40% | 25% | 27% | 18% | 18% | 16% | 16% | 11% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 37.78% | -22.58% | 14.58% | 29.09% | -8.45% | 47.69% | 41.67% | 8.09% | 21.77% | 44.13% | 31.40% |
| Change in YoY Net Profit Growth (%) | 0.00% | -60.36% | 37.16% | 14.51% | -37.54% | 56.14% | -6.03% | -33.58% | 13.68% | 22.37% | -12.74% |
Poly Medicure Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 19% |
| 3 Years: | 22% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 29% |
| 3 Years: | 34% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 35% |
| 3 Years: | 33% |
| 1 Year: | -21% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 12:20 pm
Balance Sheet
Last Updated: November 9, 2025, 2:43 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 44 | 44 | 44 | 44 | 48 | 48 | 48 | 48 | 51 | 51 |
| Reserves | 124 | 174 | 207 | 227 | 294 | 337 | 391 | 918 | 1,040 | 1,194 | 1,422 | 2,715 | 2,868 |
| Borrowings | 67 | 79 | 82 | 101 | 133 | 161 | 207 | 137 | 127 | 149 | 174 | 180 | 240 |
| Other Liabilities | 73 | 89 | 76 | 85 | 94 | 112 | 126 | 121 | 163 | 187 | 215 | 246 | 429 |
| Total Liabilities | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,587 |
| Fixed Assets | 123 | 165 | 182 | 207 | 265 | 306 | 363 | 426 | 488 | 635 | 867 | 1,084 | 1,439 |
| CWIP | 20 | 10 | 14 | 20 | 18 | 19 | 25 | 21 | 43 | 78 | 76 | 101 | 83 |
| Investments | 3 | 4 | 4 | 3 | 17 | 8 | 25 | 354 | 346 | 126 | 167 | 1,077 | 930 |
| Other Assets | 140 | 185 | 187 | 227 | 264 | 321 | 354 | 422 | 499 | 738 | 748 | 930 | 1,135 |
| Total Assets | 286 | 364 | 387 | 457 | 565 | 654 | 767 | 1,224 | 1,377 | 1,577 | 1,859 | 3,192 | 3,587 |
Below is a detailed analysis of the balance sheet data for Poly Medicure Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 51.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,868.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,715.00 Cr. (Mar 2025) to 2,868.00 Cr., marking an increase of 153.00 Cr..
- For Borrowings, as of Sep 2025, the value is 240.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 180.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 60.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 429.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 246.00 Cr. (Mar 2025) to 429.00 Cr., marking an increase of 183.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,587.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,192.00 Cr. (Mar 2025) to 3,587.00 Cr., marking an increase of 395.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,439.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,084.00 Cr. (Mar 2025) to 1,439.00 Cr., marking an increase of 355.00 Cr..
- For CWIP, as of Sep 2025, the value is 83.00 Cr.. The value appears to be declining and may need further review. It has decreased from 101.00 Cr. (Mar 2025) to 83.00 Cr., marking a decrease of 18.00 Cr..
- For Investments, as of Sep 2025, the value is 930.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,077.00 Cr. (Mar 2025) to 930.00 Cr., marking a decrease of 147.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 930.00 Cr. (Mar 2025) to 1,135.00 Cr., marking an increase of 205.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,587.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,192.00 Cr. (Mar 2025) to 3,587.00 Cr., marking an increase of 395.00 Cr..
Notably, the Reserves (2,868.00 Cr.) exceed the Borrowings (240.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 9.00 | 7.00 | 6.00 | -8.00 | -11.00 | -30.00 | -41.00 | 79.00 | 88.00 | 118.00 | 187.00 | 275.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 59 | 74 | 77 | 79 | 77 | 68 | 72 | 82 | 77 | 72 | 76 |
| Inventory Days | 142 | 148 | 114 | 194 | 161 | 186 | 241 | 217 | 218 | 237 | 205 | 233 |
| Days Payable | 101 | 101 | 76 | 131 | 96 | 123 | 142 | 111 | 115 | 105 | 89 | 71 |
| Cash Conversion Cycle | 94 | 106 | 111 | 140 | 144 | 139 | 166 | 179 | 185 | 209 | 188 | 239 |
| Working Capital Days | 20 | 25 | 35 | 55 | 71 | 56 | 44 | 74 | 81 | 69 | 54 | 74 |
| ROCE % | 33% | 30% | 26% | 24% | 26% | 22% | 25% | 22% | 17% | 18% | 24% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| UTI Flexi Cap Fund | 2,144,773 | 1.24 | 312.42 | 2,144,773 | 2025-04-22 16:11:32 | 0% |
| Quant Small Cap Fund | 1,043,752 | 0.97 | 152.04 | 1,043,752 | 2025-04-22 16:11:32 | 0% |
| UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan | 180,609 | 0.5 | 26.31 | 180,609 | 2025-04-22 07:46:55 | 0% |
| UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan | 180,609 | 0.5 | 26.31 | 180,609 | 2025-04-22 05:20:40 | 0% |
| WhiteOak Capital Flexi Cap Fund | 140,638 | 0.69 | 20.49 | 140,638 | 2025-04-22 15:56:54 | 0% |
| Bank of India Small Cap Fund | 96,500 | 1.54 | 14.06 | 96,500 | 2025-04-22 15:56:54 | 0% |
| UTI Healthcare Fund | 62,328 | 0.99 | 9.08 | 62,328 | 2025-04-22 15:56:54 | 0% |
| WhiteOak Capital Mid Cap Fund | 51,906 | 0.49 | 7.56 | 51,906 | 2025-04-22 15:56:54 | 0% |
| Bank of India ELSS Tax Saver | 49,768 | 0.66 | 7.25 | 49,768 | 2025-04-22 16:11:32 | 0% |
| Bank of India ELSS Tax Saver - Eco Plan | 49,768 | 0.66 | 7.25 | 49,768 | 2025-04-22 15:56:54 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 34.13 | 26.92 | 18.69 | 15.28 | 15.25 |
| Diluted EPS (Rs.) | 34.11 | 26.90 | 18.67 | 15.27 | 15.24 |
| Cash EPS (Rs.) | 41.06 | 33.31 | 24.44 | 20.65 | 18.78 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 272.95 | 153.18 | 129.41 | 113.40 | 100.71 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 272.95 | 153.18 | 129.41 | 113.40 | 100.71 |
| Revenue From Operations / Share (Rs.) | 164.80 | 143.35 | 116.24 | 96.25 | 82.03 |
| PBDIT / Share (Rs.) | 53.49 | 43.45 | 31.43 | 26.17 | 24.28 |
| PBIT / Share (Rs.) | 45.33 | 36.79 | 25.47 | 20.55 | 19.32 |
| PBT / Share (Rs.) | 44.15 | 35.61 | 24.55 | 20.10 | 18.43 |
| Net Profit / Share (Rs.) | 32.90 | 26.65 | 18.48 | 15.02 | 13.83 |
| NP After MI And SOA / Share (Rs.) | 33.41 | 26.91 | 18.69 | 15.28 | 14.17 |
| PBDIT Margin (%) | 32.45 | 30.30 | 27.04 | 27.19 | 29.59 |
| PBIT Margin (%) | 27.50 | 25.66 | 21.91 | 21.34 | 23.55 |
| PBT Margin (%) | 26.78 | 24.83 | 21.12 | 20.88 | 22.47 |
| Net Profit Margin (%) | 19.96 | 18.58 | 15.90 | 15.60 | 16.85 |
| NP After MI And SOA Margin (%) | 20.27 | 18.77 | 16.07 | 15.87 | 17.27 |
| Return on Networth / Equity (%) | 12.24 | 17.56 | 14.43 | 13.47 | 14.07 |
| Return on Capital Employeed (%) | 16.27 | 23.42 | 19.03 | 17.13 | 17.60 |
| Return On Assets (%) | 10.60 | 13.89 | 11.36 | 10.64 | 11.10 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.01 | 0.03 | 0.06 |
| Total Debt / Equity (X) | 0.06 | 0.11 | 0.11 | 0.11 | 0.10 |
| Asset Turnover Ratio (%) | 0.66 | 0.80 | 0.73 | 0.68 | 0.76 |
| Current Ratio (X) | 5.18 | 2.40 | 2.75 | 3.46 | 4.12 |
| Quick Ratio (X) | 4.41 | 1.77 | 2.04 | 2.71 | 3.38 |
| Inventory Turnover Ratio (X) | 2.26 | 2.16 | 2.25 | 2.39 | 2.22 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 11.14 | 13.37 | 16.36 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 8.93 | 10.14 | 11.95 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 88.86 | 86.63 | 83.64 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 91.07 | 89.86 | 88.05 | 0.00 |
| Interest Coverage Ratio (X) | 45.18 | 36.90 | 34.12 | 58.99 | 27.35 |
| Interest Coverage Ratio (Post Tax) (X) | 28.79 | 23.63 | 21.07 | 34.86 | 16.57 |
| Enterprise Value (Cr.) | 22744.56 | 15271.32 | 9107.85 | 9208.87 | 7911.73 |
| EV / Net Operating Revenue (X) | 13.62 | 11.10 | 8.17 | 9.98 | 10.06 |
| EV / EBITDA (X) | 41.97 | 36.62 | 30.20 | 36.69 | 33.99 |
| MarketCap / Net Operating Revenue (X) | 13.61 | 11.08 | 8.20 | 9.86 | 9.97 |
| Retention Ratios (%) | 0.00 | 88.85 | 86.62 | 83.63 | 0.00 |
| Price / BV (X) | 8.21 | 10.37 | 7.36 | 8.37 | 8.12 |
| Price / Net Operating Revenue (X) | 13.61 | 11.08 | 8.20 | 9.86 | 9.97 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Poly Medicure Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 34.13. This value is within the healthy range. It has increased from 26.92 (Mar 24) to 34.13, marking an increase of 7.21.
- For Diluted EPS (Rs.), as of Mar 25, the value is 34.11. This value is within the healthy range. It has increased from 26.90 (Mar 24) to 34.11, marking an increase of 7.21.
- For Cash EPS (Rs.), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 41.06, marking an increase of 7.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 272.95. It has increased from 153.18 (Mar 24) to 272.95, marking an increase of 119.77.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 164.80. It has increased from 143.35 (Mar 24) to 164.80, marking an increase of 21.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.49. This value is within the healthy range. It has increased from 43.45 (Mar 24) to 53.49, marking an increase of 10.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 45.33. This value is within the healthy range. It has increased from 36.79 (Mar 24) to 45.33, marking an increase of 8.54.
- For PBT / Share (Rs.), as of Mar 25, the value is 44.15. This value is within the healthy range. It has increased from 35.61 (Mar 24) to 44.15, marking an increase of 8.54.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 32.90. This value is within the healthy range. It has increased from 26.65 (Mar 24) to 32.90, marking an increase of 6.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.41. This value is within the healthy range. It has increased from 26.91 (Mar 24) to 33.41, marking an increase of 6.50.
- For PBDIT Margin (%), as of Mar 25, the value is 32.45. This value is within the healthy range. It has increased from 30.30 (Mar 24) to 32.45, marking an increase of 2.15.
- For PBIT Margin (%), as of Mar 25, the value is 27.50. This value exceeds the healthy maximum of 20. It has increased from 25.66 (Mar 24) to 27.50, marking an increase of 1.84.
- For PBT Margin (%), as of Mar 25, the value is 26.78. This value is within the healthy range. It has increased from 24.83 (Mar 24) to 26.78, marking an increase of 1.95.
- For Net Profit Margin (%), as of Mar 25, the value is 19.96. This value exceeds the healthy maximum of 10. It has increased from 18.58 (Mar 24) to 19.96, marking an increase of 1.38.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 20.27. This value exceeds the healthy maximum of 20. It has increased from 18.77 (Mar 24) to 20.27, marking an increase of 1.50.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.24. This value is below the healthy minimum of 15. It has decreased from 17.56 (Mar 24) to 12.24, marking a decrease of 5.32.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.27. This value is within the healthy range. It has decreased from 23.42 (Mar 24) to 16.27, marking a decrease of 7.15.
- For Return On Assets (%), as of Mar 25, the value is 10.60. This value is within the healthy range. It has decreased from 13.89 (Mar 24) to 10.60, marking a decrease of 3.29.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.06, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.66. It has decreased from 0.80 (Mar 24) to 0.66, marking a decrease of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 5.18. This value exceeds the healthy maximum of 3. It has increased from 2.40 (Mar 24) to 5.18, marking an increase of 2.78.
- For Quick Ratio (X), as of Mar 25, the value is 4.41. This value exceeds the healthy maximum of 2. It has increased from 1.77 (Mar 24) to 4.41, marking an increase of 2.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.26. This value is below the healthy minimum of 4. It has increased from 2.16 (Mar 24) to 2.26, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.14 (Mar 24) to 0.00, marking a decrease of 11.14.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 8.93 (Mar 24) to 0.00, marking a decrease of 8.93.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.86 (Mar 24) to 0.00, marking a decrease of 88.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 91.07 (Mar 24) to 0.00, marking a decrease of 91.07.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 45.18. This value is within the healthy range. It has increased from 36.90 (Mar 24) to 45.18, marking an increase of 8.28.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 28.79. This value is within the healthy range. It has increased from 23.63 (Mar 24) to 28.79, marking an increase of 5.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22,744.56. It has increased from 15,271.32 (Mar 24) to 22,744.56, marking an increase of 7,473.24.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.62. This value exceeds the healthy maximum of 3. It has increased from 11.10 (Mar 24) to 13.62, marking an increase of 2.52.
- For EV / EBITDA (X), as of Mar 25, the value is 41.97. This value exceeds the healthy maximum of 15. It has increased from 36.62 (Mar 24) to 41.97, marking an increase of 5.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 88.85 (Mar 24) to 0.00, marking a decrease of 88.85.
- For Price / BV (X), as of Mar 25, the value is 8.21. This value exceeds the healthy maximum of 3. It has decreased from 10.37 (Mar 24) to 8.21, marking a decrease of 2.16.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has increased from 11.08 (Mar 24) to 13.61, marking an increase of 2.53.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Poly Medicure Ltd:
- Net Profit Margin: 19.96%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.27% (Industry Average ROCE: 13.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.24% (Industry Average ROE: 10.35%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 28.79
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 53.2 (Industry average Stock P/E: 26.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.96%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | No. 232-B, 3rd Floor, New Delhi Delhi 110020 | investorcare@polymedicure.com http://www.polymedicure.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Devendra Raj Mehta | Chairman |
| Mr. Himanshu Baid | Managing Director |
| Mr. Rishi Baid | Joint Managing Director |
| Mr. Jugal Kishore Baid | Non Executive Director |
| Mrs. Mukulika Baid | Non Executive Director |
| Mr. Alessandro Balboni | Non Executive Director |
| Dr. Shailendra Raj Mehta | Ind. Non-Executive Director |
| Dr. Ambrish Mithal | Ind. Non-Executive Director |
| Dr. Sandeep Bhargava | Ind. Non-Executive Director |
| Mr. Vimal Bhandari | Ind. Non-Executive Director |
| Mr. Amit Khosla | Ind. Non-Executive Director |
| Ms. Sonal Mattoo | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Poly Medicure Ltd?
Poly Medicure Ltd's intrinsic value (as of 27 November 2025) is 1940.14 which is 2.11% higher the current market price of 1,900.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 19,252 Cr. market cap, FY2025-2026 high/low of 3,032/1,821, reserves of ₹2,868 Cr, and liabilities of 3,587 Cr.
What is the Market Cap of Poly Medicure Ltd?
The Market Cap of Poly Medicure Ltd is 19,252 Cr..
What is the current Stock Price of Poly Medicure Ltd as on 27 November 2025?
The current stock price of Poly Medicure Ltd as on 27 November 2025 is 1,900.
What is the High / Low of Poly Medicure Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Poly Medicure Ltd stocks is 3,032/1,821.
What is the Stock P/E of Poly Medicure Ltd?
The Stock P/E of Poly Medicure Ltd is 53.2.
What is the Book Value of Poly Medicure Ltd?
The Book Value of Poly Medicure Ltd is 288.
What is the Dividend Yield of Poly Medicure Ltd?
The Dividend Yield of Poly Medicure Ltd is 0.18 %.
What is the ROCE of Poly Medicure Ltd?
The ROCE of Poly Medicure Ltd is 20.1 %.
What is the ROE of Poly Medicure Ltd?
The ROE of Poly Medicure Ltd is 15.8 %.
What is the Face Value of Poly Medicure Ltd?
The Face Value of Poly Medicure Ltd is 5.00.